Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.837
+0.004 (0.42%)
At close: Sep 18, 2024, 4:00 PM
0.859
+0.022 (2.66%)
After-hours: Sep 18, 2024, 5:54 PM EDT
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for SGMO stock have an average target of 2.67, with a low estimate of 1.00 and a high estimate of 5.00. The average target predicts an increase of 218.96% from the current stock price of 0.84.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SGMO stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +497.30% | Aug 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +497.30% | Jul 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +497.30% | Jul 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +497.30% | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 → $5 | Strong Buy | Reiterates | $3 → $5 | +497.30% | Mar 19, 2024 |
Financial Forecast
Revenue This Year
55.39M
from 176.23M
Decreased by -68.57%
Revenue Next Year
84.21M
from 55.39M
Increased by 52.02%
EPS This Year
-0.51
from -1.48
EPS Next Year
-0.23
from -0.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 153.3M | 212.1M | 158.6M | ||
| Avg | 55.4M | 84.2M | 100.3M | ||
| Low | 980,000 | 19.6M | 24.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -13.0% | 282.9% | 88.3% | ||
| Avg | -68.6% | 52.0% | 19.1% | ||
| Low | -99.4% | -64.6% | -71.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.02 | 0.19 | 0.03 | ||
| Avg | -0.51 | -0.23 | -0.17 | ||
| Low | -0.70 | -0.58 | -0.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.